SCHEMBL6320765

SCHEMBL6320765

COc1ccc(C(Cl)=C2C(=O)N(C(C)=O)c3ccccc32)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 2/20 0.50
NPC1 O15118 2/20 0.46
HSP90AA1 P07900 1/20 0.46
MEN1 O00255 1/20 0.43
USP2 O75604 1/20 0.43
MAPT P10636 1/20 0.43
CASP1 P29466 1/20 0.43
BRCA1 P38398 1/20 0.43
KMT2A Q03164 1/20 0.43
ALDH1A1 P00352 1/20 0.43
BCHE P06276 3/20 0.43
ACHE P22303 2/20 0.43
GAA P10253 1/20 0.43
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
RAB9A P51151 1/20 0.40
PAX8 Q06710 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6320761 1.00 CES1 (0.50) CES1NPC1HSP90AA1MEN1USP2
SCHEMBL6322399 0.87 CES1 (0.47) CES1NPC1MEN1MAPTKMT2A
SCHEMBL6322402 0.87 CES1 (0.47) CES1NPC1MEN1MAPTKMT2A
SCHEMBL6328153 0.87 CES1 (0.58) CES1NPC1MEN1USP2MAPT
SCHEMBL6328148 0.87 CES1 (0.58) CES1NPC1MEN1USP2MAPT
SCHEMBL6321119 0.86 CES1 (0.54) CES1NPC1HSP90AA1MEN1USP2
SCHEMBL6328121 0.86 CES1 (0.54) CES1NPC1MEN1USP2MAPT
SCHEMBL6321121 0.86 CES1 (0.54) CES1NPC1HSP90AA1MEN1USP2
SCHEMBL6328120 0.86 CES1 (0.54) CES1NPC1MEN1USP2MAPT
SCHEMBL8016552 0.85 CES1 (0.52) CES1NPC1HSP90AA1MEN1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6855710-B2 Substituted indolines with an inhibitory effect on various kinases and complexes of CDKs BOEHRINGER INGELHEIM PHARMA KG (DE) 2005-02-15 US disclosed
US-20040058978-A1 Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058978-A1 Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs CDK1, CDK2, CDK3 CES1 2292/4885NPC1 4477/4885HSP90AA1 3374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.